GPR19 Antibody

What is GPR19 and why is it important in research?

GPR19 is an orphan G protein-coupled receptor encoded by the GPR19 gene in humans. It is also known as probable G-protein coupled receptor 19 and GPR-NGA. The protein has a molecular weight of approximately 47.7 kilodaltons . GPR19 has gained scientific interest due to its expression pattern in specific tissues and potential role in certain cancers, particularly lung adenocarcinomas and neuroendocrine tumors . The receptor's expression in these tumors suggests it may serve as a suitable diagnostic or therapeutic target, making it valuable for cancer research .

What types of GPR19 antibodies are available for research?

Multiple suppliers offer various types of GPR19 antibodies for research purposes. These include:

• Polyclonal antibodies targeting different epitopes (such as C-terminal regions)

• Unconjugated antibodies for general detection

• Species-specific antibodies with reactivity to human, mouse, rat, and other species

The antibodies vary in their applications, with many suitable for Western blot (WB), enzyme-linked immunosorbent assay (ELISA), immunocytochemistry (ICC), immunofluorescence (IF), and immunohistochemistry (IHC) . For instance, some suppliers offer antibodies that target the C-terminal region of GPR19, while others target the third extracellular loop of the receptor .

How is GPR19 expression distributed in normal human tissues?

GPR19 expression in normal human tissues is limited to specific cell populations, as determined by immunohistochemical studies. The expression pattern includes:

• A distinct cell population within the cortex (primarily in layers II and VI), which appear to be astrocytes

• Single cells within pancreatic islets

• Intestinal ganglia

• Gastric chief cells

• Endocrine cells in various locations:

  • Bronchial tract

  • Gastrointestinal tract (decreasing frequency from duodenum to colon)

  • Prostate

GPR19 is notably absent in the thyroid gland, alveolar tissue of the lung, heart, spleen, kidneys, lymph nodes, acinar cells of the exocrine pancreas, and testicular, breast, ovarian, or uterine tissue .

How can researchers verify the specificity of GPR19 antibodies?

Researchers can verify GPR19 antibody specificity through several complementary approaches:

• siRNA knockdown validation: Treat cells expressing GPR19 endogenously (such as OH-1 or NCI-h82 cell lines) with GPR19-specific siRNA and observe the reduction in immunosignal compared to controls .

• Peptide competition assay: Preincubate the antibody with the immunizing peptide before application to samples. Specific antibodies will show complete abolishment of the immunosignal .

• Western blot analysis: Perform Western blot using membrane preparations from GPR19-expressing cells. A specific antibody should recognize a band at the expected molecular weight of approximately 48 kDa .

• Comparison with other antibodies: Compare staining patterns with other commercially available antibodies targeting different epitopes of GPR19 to confirm similar but not identical patterns .

• Negative controls: Include tissues known to lack GPR19 expression as negative controls in experiments.

What are the optimal conditions for immunohistochemical detection of GPR19?

Based on the research described in the search results, optimal conditions for immunohistochemical detection of GPR19 in formalin-fixed, paraffin-embedded tissues include:

• Antibody selection: Use of a validated antibody targeting the C-terminus of human GPR19 (such as the antibody described in the search results, which targets residues 395-415) .

• Antibody dilution: Optimize antibody concentration (1:100 dilution was used in the referenced study for immunocytochemistry) .

• Fixation protocol: Fix samples with 4% paraformaldehyde and 0.2% picric acid in phosphate buffer (pH 6.9) for 20 minutes at room temperature .

• Incubation parameters: Incubate with the primary antibody overnight at 4°C, followed by appropriate secondary antibody incubation (e.g., Alexa Fluor 488-conjugated secondary antibody at 1:5,000 dilution for 2 hours) .

• Controls: Include appropriate positive and negative controls, as well as peptide competition controls to ensure specificity.

What scoring systems can be used to quantify GPR19 expression in tissue samples?

The Immunoreactivity Score (IRS) system was utilized in the referenced study to quantify GPR19 expression. This scoring system evaluates both the percentage of positively stained cells and the intensity of the staining .

The IRS values range from 0 to 12, with higher scores indicating stronger expression. The scoring allows for objective comparison between different tissue samples and tumor types. For example:

• IRS ≥ 3 is often considered positive expression

• IRS 0-2 indicates negative or very low expression

• IRS ≥ 8 represents high expression

Using this system, researchers found substantial variability in GPR19 expression both between and within tumor entities, with some tissues showing strong staining only in small areas .

How does GPR19 expression differ across various tumor types?

Strong GPR19 expression is particularly prevalent in lung tumors (except for squamous cell carcinomas), with notable expression also observed in medullary thyroid carcinomas, parathyroid adenomas, and pheochromocytomas .

What is the correlation between GPR19 expression and clinical outcomes in lung cancer?

Research indicates that GPR19 expression in lung tumors correlates with clinical outcomes in interesting ways:

• Negative correlation with proliferation: GPR19 expression shows a negative correlation with the expression of Ki-67, a well-established proliferation marker .

• Positive correlation with survival: Higher GPR19 expression is associated with better patient survival in lung cancer cases .

These correlations suggest that GPR19 might have a role in tumor biology that differs from promoting aggressive growth. Instead, it may be associated with more differentiated or less aggressive tumor phenotypes, which typically have better clinical outcomes. This makes GPR19 not only a potential diagnostic marker but also a prognostic indicator in lung cancer patients .

How might GPR19 serve as a diagnostic or therapeutic target in cancer?

GPR19 shows promise as both a diagnostic and therapeutic target in cancer, particularly in lung adenocarcinomas and neuroendocrine tumors, for several reasons:

• Selective expression pattern: GPR19 shows limited expression in normal tissues but is strongly expressed in specific tumor types, creating a favorable therapeutic window .

• Diagnostic potential: The distinct expression pattern in certain tumor types (especially lung adenocarcinomas and neuroendocrine tumors) makes GPR19 a potentially valuable diagnostic marker for pathological assessment .

• Targetable receptor class: As a G protein-coupled receptor, GPR19 belongs to a class of proteins that are traditionally druggable targets, accessible at the cell surface, and amenable to both small molecule and antibody-based therapeutics.

• Association with survival: The positive correlation with patient survival suggests GPR19 could serve as a prognostic biomarker in lung cancer patients .

• Potential for targeted therapy: The preferential expression in certain tumor types opens the possibility for targeted therapeutic approaches, such as antibody-drug conjugates or receptor-targeted small molecules.

What are the key technical challenges in detecting GPR19 in tissue samples?

Researchers face several technical challenges when detecting GPR19 in tissue samples:

How can researchers optimize Western blot protocols for GPR19 detection?

Based on the methods described in the search results, researchers can optimize Western blot protocols for GPR19 detection using these guidelines:

• Sample preparation: Use membrane preparations rather than whole cell lysates to enrich for membrane proteins like GPR19 .

• Antibody selection: Use a validated antibody targeting the C-terminus of human GPR19, which has shown specificity in detecting a band at approximately 48 kDa .

• Controls:

  • Include positive controls (cell lines known to express GPR19, such as OH-1)

  • Implement negative controls through GPR19 knockdown using siRNA

  • Use peptide competition controls by preincubating the antibody with the immunizing peptide

• Expected results: A specific GPR19 signal should appear at approximately 48 kDa, consistent with the reported molecular weight of the human receptor .

• Validation: Confirm specificity by showing signal reduction after GPR19 knockdown and complete signal extinction after peptide competition .

What approaches can be used to study GPR19 function in cell culture models?

Several approaches can be employed to study GPR19 function in cell culture models:

• Expression manipulation:

  • siRNA knockdown: As demonstrated in the search results, GPR19-specific siRNA can effectively reduce receptor expression in cells expressing GPR19 endogenously (such as OH-1 or NCI-h82 cell lines) .

  • Overexpression systems: Transfect cells with GPR19 expression constructs to study the effects of increased receptor levels.

• Functional assays:

  • Signaling studies: Investigate downstream signaling pathways activated by GPR19.

  • Proliferation assays: Examine the impact of GPR19 expression on cell proliferation, particularly given the negative correlation with Ki-67 observed in tumors .

  • Migration and invasion assays: Assess whether GPR19 affects cell motility and invasive capacity.

• Imaging techniques:

  • Immunocytochemistry: Visualize receptor localization using specific antibodies, as demonstrated in the OH-1 and NCI-h82 cell lines .

  • Live cell imaging: Study receptor trafficking and internalization in real-time.

• Co-expression studies:

  • Investigate co-expression with other markers to understand the cellular context of GPR19 function.

  • The double-labeling fluorescence experiments for chromogranin A used in tissue sections could be adapted for cell culture models .

What are the promising avenues for future research on GPR19 antibodies?

Several promising research directions for GPR19 antibodies include:

• Development of monoclonal antibodies: While the search results describe a polyclonal antibody, developing monoclonal antibodies against GPR19 could provide more consistent and specific tools for research and potential therapeutic applications.

• Therapeutic antibodies: Investigating antibodies that can modulate GPR19 function rather than just detect it, potentially leading to therapeutic applications in GPR19-expressing tumors.

• Antibody-drug conjugates: Leveraging the selective expression of GPR19 in certain tumors by developing antibody-drug conjugates for targeted cancer therapy.

• Improved detection methods: Developing more sensitive detection methods for GPR19 in tissues with low expression levels.

• Cross-species antibodies: Creating and validating antibodies that work across different species to facilitate translational research from animal models to humans.

What is the significance of GPR19 being an orphan receptor, and how might this impact antibody-based research?

GPR19 is classified as an orphan G protein-coupled receptor, meaning its endogenous ligand(s) remain unknown . This orphan status has several implications for antibody-based research:

• Functional characterization challenges: Without known ligands, understanding the physiological role of GPR19 and its signaling pathways is more challenging, making it difficult to fully interpret the significance of its expression patterns.

• Antibody-based functional studies: Antibodies may serve not only as detection tools but also as potential modulators of receptor function, potentially acting as surrogate ligands (agonists or antagonists).

• Conformational considerations: GPR19 may adopt different conformational states that could affect antibody binding, particularly if the receptor has constitutive activity in the absence of a known ligand.

• Target validation complexity: The lack of known ligands makes it more challenging to validate GPR19 as a therapeutic target, increasing the importance of antibody-based detection to establish expression patterns and correlations with disease.

• Discovery opportunities: Antibodies against GPR19 could be used in screens to identify potential endogenous ligands, thereby de-orphanizing the receptor and opening new research avenues.

How might single-cell analysis techniques enhance our understanding of GPR19 expression patterns?

The search results indicate that GPR19 expression is often limited to specific cell populations and shows heterogeneous expression within tumors . Single-cell analysis techniques could significantly enhance our understanding of GPR19 expression patterns by:

• Resolving cellular heterogeneity: Identifying specific cell types expressing GPR19 within complex tissues, particularly in settings where expression is limited to rare cell populations.

• Correlating with cell states: Determining whether GPR19 expression is associated with particular cellular states or differentiation stages.

• Co-expression patterns: Identifying genes and proteins co-expressed with GPR19 at the single-cell level, providing insights into its functional role and regulatory networks.

• Spatial context: Combining single-cell analysis with spatial transcriptomics or multiplexed immunofluorescence to understand the localization of GPR19-expressing cells within the tumor microenvironment.

• Temporal dynamics: Tracking changes in GPR19 expression during disease progression or in response to treatments.

• Improved quantification: Providing more accurate quantification of GPR19 expression levels across diverse cell populations, addressing the limitations of tissue-level analyses where strong expression in a small subset of cells might be diluted in bulk measurements.